4-Borono-2-[18F]fluoro-D,L-phenylalanine as a target compound for boron neutron capture therapy: tumor imaging potential with positron emission tomography.
We studied the tumor uptake and metabolism of 4-borono-2-[18F]fluoro-D,L-phenylalanine ([18F]FBPA), an 18F-labeled target compound for boron neutron capture therapy. In mice bearing FM3A mammary carcinoma, the accumulation of [18F]FBPA in the FM3A for the first 2 h, and its decrease in all other tissues, resulted in high FM3A-to-tissue uptake ratios. In the FM3A, the tracer was stable for metabolic alteration, which was in contrast to the gradual increase of protein-bound radioactivity in plasma. Imaging of FM3A was demonstrated by whole body autoradiography. [18F]FBPA has potential for use as a PET tracer for tumor imaging with high contrast, even in the pancreas.
Ishiwata
K
K
Division of Radiopharmaceutical Chemistry, Tohoku University, Sendai, Japan.
Ido
T
T
Kawamura
M
M
Kubota
K
K
Ichihashi
M
M
Mishima
Y
Y
D000818:Animals; D001345:Autoradiography; D001896:Boron Compounds / Q000493:pharmacokinetics; D002851:Chromatography, High Pressure Liquid; D005462:Fluorine Radioisotopes / Q000493:pharmacokinetics; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000000981:diagnostic imaging* / Q000378:metabolism; D051379:Mice; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D014055:Tomography, Emission-Computed
D001896:Boron Compounds; D005462:Fluorine Radioisotopes; C072915:4-borono-2-fluorophenylalanine; D010649:Phenylalanine